Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 3/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543359 | 1.00 | GAA (0.56) | GAACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL29833544 | 1.00 | GAA (0.56) | GAACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL7445733 | 0.93 | GAA (0.52) | GAACYP1A2CYP2C9CYP2C19MAPT | |
| Cadaverine Tartrate SCHEMBL10907406 | 0.93 | GAA (0.53) | GAACYP1A2CYP2C9CYP2C19MAPT | |
| Cadaverine Tartrate SCHEMBL4805487 | 0.93 | GAA (0.53) | GAACYP1A2CYP2C9CYP2C19MAPT | |
| Cadaverine Tartrate SCHEMBL4805491 | 0.93 | GAA (0.53) | GAACYP1A2CYP2C9CYP2C19MAPT | |
| Cadaverine Tartrate SCHEMBL10907408 | 0.93 | GAA (0.53) | GAACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL7438830 | 0.92 | GAA (0.52) | GAACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL7356369 | 0.88 | OPRL1 (0.50) | ACE | |
| SCHEMBL2222575 | 0.88 | OPRL1 (0.50) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425550-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7098235-B2 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | disclosed |
| US-7057046-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | disclosed |
| US-5679671-A | ANGIOTENSIN 1-CONVERTING ENZYME INHIBITOR, VASOPRESSIN ANTAGONISM AND ATRIAL NAUTRIURETIC PEPTIDE HYDROLASE INHIBITOR | EISAI CO., LTD. (JP) | 1997-10-21 | — | — | US | disclosed |
| EP-0671172-A1 | AMINO ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-09-13 | — | — | EP | disclosed |
| US-4575503-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1986-03-11 | — | — | US | disclosed |
| US-4473575-A | ANGIOTENSIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-09-25 | — | — | US | disclosed |
| US-4410520-A | ANGIOTENSION CONVERTING ENZYME INGIBITOR, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| EP-0072352-A1 | Benzazepin-2-ones, process for their preparation, pharmaceutical preparations containing these compounds and the compounds for therapeutical use | CIBA-GEIGY AG (CH) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | PYGL, PNLIP, PYGM | GAA 43/4885CYP1A2 710/4885CYP2C9 541/4885 |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | GAA 23/4885CYP1A2 190/4885CYP2C9 292/4885 |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS1 | GAA 28/4885CYP1A2 342/4885CYP2C9 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.